Literature DB >> 15596860

Sindbis virus with a tricomponent genome.

Rafik Fayzulin1, Rodion Gorchakov, Olga Petrakova, Evgenia Volkova, Ilya Frolov.   

Abstract

We established a system for propagation of Sindbis virus (SIN)-based replicons in tissue culture in the form of a tricomponent genome virus. Three RNA fragments containing complementing genetic information required for virus replication are packaged into separate viral particles, and each cell produces at least 1,000 packaged replicons and the number of packaged helpers sufficient to perform the next passage. This system can be used to generate large stocks of packaged replicons. The formation of infectious recombinant SIN virus was not detected in any experiments. These features make multicomponent genome SIN an attractive system for a variety of research and biotechnology applications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15596860      PMCID: PMC538738          DOI: 10.1128/JVI.79.1.637-643.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-sensitive marker, and in vitro mutagenesis to generate defined mutants.

Authors:  C M Rice; R Levis; J H Strauss; H V Huang
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Complete nucleotide sequence of the genomic RNA of Sindbis virus.

Authors:  E G Strauss; C M Rice; J H Strauss
Journal:  Virology       Date:  1984-02       Impact factor: 3.616

Review 3.  Alphavirus vectors for gene therapy applications.

Authors:  K Lundstrom
Journal:  Curr Gene Ther       Date:  2001-05       Impact factor: 4.391

4.  Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates.

Authors:  Randal J Schoepp; Jonathan F Smith; Michael D Parker
Journal:  Virology       Date:  2002-10-25       Impact factor: 3.616

5.  Sindbis virus: an efficient, broad host range vector for gene expression in animal cells.

Authors:  C Xiong; R Levis; P Shen; S Schlesinger; C M Rice; H V Huang
Journal:  Science       Date:  1989-03-03       Impact factor: 47.728

Review 6.  Alphavirus vectors for cancer gene therapy (review).

Authors:  Ryuya Yamanaka
Journal:  Int J Oncol       Date:  2004-04       Impact factor: 5.650

Review 7.  Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine.

Authors:  Shane Crotty; Raul Andino
Journal:  Adv Drug Deliv Rev       Date:  2004-04-19       Impact factor: 15.470

8.  RNAs from two independently isolated defective interfering particles of Sindbis virus contain a cellular tRNA sequence at their 5' ends.

Authors:  S S Monroe; S Schlesinger
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

Review 9.  Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases.

Authors:  Philip M McKenna; James P McGettigan; Roger J Pomerantz; Bernhard Dietzschold; Matthias J Schnell
Journal:  Curr HIV Res       Date:  2003-04       Impact factor: 1.581

10.  Sequence analysis of cDNA's derived from the RNA of Sindbis virions and of defective interfering particles.

Authors:  S S Monroe; J H Ou; C M Rice; S Schlesinger; E G Strauss; J H Strauss
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

View more
  11 in total

1.  Sindbis virus nonstructural protein nsP2 is cytotoxic and inhibits cellular transcription.

Authors:  Natalia Garmashova; Rodion Gorchakov; Elena Frolova; Ilya Frolov
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Development of Sindbis viruses encoding nsP2/GFP chimeric proteins and their application for studying nsP2 functioning.

Authors:  Svetlana Atasheva; Rodion Gorchakov; Robert English; Ilya Frolov; Elena Frolova
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

3.  In vivo packaging of brome mosaic virus RNA3, but not RNAs 1 and 2, is dependent on a cis-acting 3' tRNA-like structure.

Authors:  Padmanaban Annamalai; A L N Rao
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

4.  The efficient packaging of Venezuelan equine encephalitis virus-specific RNAs into viral particles is determined by nsP1-3 synthesis.

Authors:  Eugenia Volkova; Rodion Gorchakov; Ilya Frolov
Journal:  Virology       Date:  2005-10-18       Impact factor: 3.616

5.  Production of pseudoinfectious yellow fever virus with a two-component genome.

Authors:  Alexandr V Shustov; Peter W Mason; Ilya Frolov
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

6.  Novel indole-2-carboxamide compounds are potent broad-spectrum antivirals active against western equine encephalitis virus in vivo.

Authors:  Phillip C Delekta; Craig J Dobry; Janice A Sindac; Scott J Barraza; Pennelope K Blakely; Jianming Xiang; Paul D Kirchhoff; Richard F Keep; David N Irani; Scott D Larsen; David J Miller
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

7.  Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins.

Authors:  Rodion Gorchakov; Eugenia Volkova; Nadezda Yun; Olga Petrakova; Nathaniel Seth Linde; Slobodan Paessler; Elena Frolova; Ilya Frolov
Journal:  Virology       Date:  2007-05-16       Impact factor: 3.616

8.  Venezuelan equine encephalitis virus capsid protein inhibits nuclear import in Mammalian but not in mosquito cells.

Authors:  Svetlana Atasheva; Natalia Garmashova; Ilya Frolov; Elena Frolova
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

9.  Properties and use of novel replication-competent vectors based on Semliki Forest virus.

Authors:  Kai Rausalu; Anna Iofik; Liane Ulper; Liis Karo-Astover; Valeria Lulla; Andres Merits
Journal:  Virol J       Date:  2009-03-24       Impact factor: 4.099

Review 10.  Alphavirus Nucleocapsid Packaging and Assembly.

Authors:  Adriano Mendes; Richard J Kuhn
Journal:  Viruses       Date:  2018-03-20       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.